TP53 codon 72 polymorphism with hepatocellular carcinoma: A meta-analysis

11Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

OBJECTIVE: The association between codon 72 polymorphism of the tumour protein p53 (TP53) gene-which results in a mis-sense mutation of arginine (R) to proline (P)-and susceptibility to hepatocellular carcinoma (HCC) is controversial. A meta-analysis was performed in order to define this relationship more precisely. METHODS: Published studies of TP53 codon 72 polymorphism and the risk of HCC were identified. Data were extracted, and summary odds ratios (OR) and 95% confidence intervals (95% CI) were calculated. Pooled ORs were determined for an additive model (R/R versus P/P), a dominant model ([R/R + R/P] versus P/P) and a recessive model (R/R versus [R/P + P/P]). RESULTS: The meta-analysis included seven case-control studies (total 1511 cases and 2165 controls). The risk of cancer was significantly decreased in the overall dominant model and the dominant model in Asian populations. A significantly decreased risk was found for all models in hospital-based but not population-based studies. There was no association between polymorphism and cancer risk when data were stratified according to hepatitis B or C virus infection status. CONCLUSION: The TP53 codon 72 polymorphism may be a risk factor for HCC. © 2012 Field House Publishing LLP.

Cite

CITATION STYLE

APA

Qin, H., Ding, C., Yu, H., & Yu, H. (2012). TP53 codon 72 polymorphism with hepatocellular carcinoma: A meta-analysis. Journal of International Medical Research, 40(2), 446–454. https://doi.org/10.1177/147323001204000206

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free